Clinically, PPARγ agonists Such as TZDs Like pioglitazone and rosiglitazone are used to treat type 2 diabetes, while PPARα agonists like fibrates target hyperlipidemia and cardiovascular risks [55]. Here, PPARA is linked to type 2 diabetes mellitus.